The DOI matches its Crossref record; 317 of the 317 references it cites were found in a registry or an index.
Localized Interleukin-12 for Cancer Immunotherapy
Open accessAbstract
Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Early clinical trials in the mid-1990's showed that systemic delivery of IL-12 incurred dose-limiting toxicities. Nevertheless, IL-12's pleiotropic activity, i.e., its ability to engage multiple effector mechanisms and reverse tumor-induced immunosuppression, continues to entice cancer researchers. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest. Diverse IL-12 delivery systems, from immunocytokine fusions to polymeric nanoparticles, have demonstrated robust antitumor immunity with reduced adverse events in preclinical studies. Several localized IL-12 delivery approaches have recently reached the clinical stage with several more at the precipice of translation. Taken together, localized delivery systems are supporting an IL-12 renaissance which may finally allow this potent cytokine to fulfill its considerable clinical potential. This review begins with a brief historical account of cytokine monotherapies and describes how IL-12 went from promising new cure to ostracized black sheep following multiple on-study deaths. The bulk of this comprehensive review focuses on developments in diverse localized delivery strategies for IL-12-based cancer immunotherapies. Advantages and limitations of different delivery technologies are highlighted. Finally, perspectives on how IL-12-based immunotherapies may be utilized for widespread clinical application in the very near future are offered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–317 of 317
Wadler, S., Levy, D. E., Frederickson, H., Falkson, C. I., Wang, Y., Weller, E. A., Burk, R. D., Ho, G. Y. F., & Kadish, A. S. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.022 · Cited by 59
Quetglas, J. I., Dubrot, J., Bezunartea, J., Sanmamed, M. F., Hervás‐Stubbs, S., Smerdou, C., & Melero, I. (2012) · Molecular Therapy · doi:10.1038/mt.2012.56 · Cited by 59
Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer
Fewell, J. G., Matar, M. M., Slobodkin, G., Han, S.-O., Rice, J. S., Hovanes, B. A., Lewis, D. H., & Anwer, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.024 · Cited by 59
Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer
Liu, X., Gao, X., Zheng, S., Wang, B., Li, Y., Zhao, C., Muftuoglu, Y., Chen, S., Li, Y., Yao, H., et al. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.04.006 · Cited by 59
Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy
Mukhopadhyay, A., Wright, J. H., Shirley, S. A., Canton, D. A., Burkart, C., Connolly, R. J., Campbell, J. S., & Pierce, R. H. (2018) · Gene Therapy · doi:10.1038/s41434-018-0044-5 · Cited by 59
Kilinc, M. O., Gu, T., Harden, J. L., Virtuoso, L. P., & Egilmez, N. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802793 · Cited by 57
Jia, S.-F., Worth, L. L., Densmore, C. L., Xu, B., Zhou, Z., & Kleinerman, E. S. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700432 · Cited by 57
Characterization of the cryoablation-induced immune response in kidney cancer patients
Kato, T., Iwasaki, T., Uemura, M., Nagahara, A., Higashihara, H., Osuga, K., Ikeda, Y., Kiyotani, K., Park, J.-H., Nonomura, N., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1326441 · Cited by 56
Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration
Tagalakis, A. D., Grosse, S. M., Meng, Q., Mustapa, M. F. M., Kwok, A., Salehi, S. E., Tabor, A. B., Hailes, H. C., & Hart, S. L. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.037 · Cited by 55
Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis
Vo, J., Yang, L., Kurtz, S. L., Smith, S. G., Koppolu, B., Ravindranathan, S., & Zaharoff, D. A. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968001 · Cited by 55
Self-citationLohr, F., Huang, Q., Hu, K., et al. (2001) · PubMed · Cited by 55
Sharifi, J., Khawli, L. A., Hu, P., King, S., & Epstein, A. L. (2001) · Hybridoma and Hybridomics · doi:10.1089/15368590152740707 · Cited by 54
Akiyama, Y., Watanabe, M., Maruyama, K., Ruscetti, F. W., Wiltrout, R. H., & Yamaguchi, K. D. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301353 · Cited by 54
Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12
Mazzolini, G. D., Narvaiza, I., Pérez‐Díez, A., Rodríguez-Calvillo, M., Qian, C., Sangro, B., Ruiz, J., Prìeto, J., Melero, I., & Quian, C. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301387 · Cited by 54
Biological behavior of human breast cancer micrometastases.
Klauber‐DeMore, N., Zee, K. J. V., Linkov, I., Borgen, P. I., & Gerald, W. L. (2001) · PubMed · Cited by 53
Maheshwari, A., Han, S.-Y., Mahato, R., & Kim, S. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301766 · Cited by 53
Yockman, J. W., Maheshwari, A., Han, S., et al. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00362-0 · Cited by 52
Eckert, F., Jelas, I., Oehme, M., Huber, S. M., Sonntag, K., Welker, C., Gillies, S. D., Strittmatter, W., Zips, D., Handgretinger, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1323161 · Cited by 52
Simpson-Abelson, M. R., Purohit, V. S., Pang, W. M., Iyer, V., Odunsi, K. O., Demmy, T. L., Yokota, S. J., Loyall, J. L., Kelleher, R. J., Balu‐Iyer, S. V., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.03.516 · Cited by 51
Electroporation‐mediated IL‐12 gene therapy in a transplantable canine cancer model
Chuang, T., Lee, S., Liao, K., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24418 · Cited by 51
Triozzi, P. L., Allen, K. O., Carlisle, R. R., Craig, M. C., LoBuglio, A. F., & Conry, R. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2283 · Cited by 51
Puca, E., Probst, P., Stringhini, M., Murer, P., Pellegrini, G., Cazzamalli, S., Hutmacher, C., Gouyou, B., Wulhfard, S., Matasci, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32603 · Cited by 51
Fewell, J. G., Matar, M. M., Rice, J. S., Brunhoeber, E., Slobodkin, G., Pence, C., Worker, M., Lewis, D. H., & Anwer, K. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1356 · Cited by 50
Melanoma: therapeutic options with recombinant interferons.
Kirkwood, J. M., & Ernstoff, M. S. (1985) · PubMed · Cited by 50
Kramer, M. G., Masner, M., Casales, E., Moreno, M., Smerdou, C., & Chabalgoity, J. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1618-x · Cited by 49
After Initial Setback, IL-12 Regaining Popularity
Jenks, S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.9.576 · Cited by 49
Tatsumi, T., Takehara, T., Yamaguchi, S., Sasakawa, A., Miyagi, T., Jinushi, M., Sakamori, R., Kohga, K., Uemura, A., Ohkawa, K., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302941 · Cited by 48
Smith, S. G., Koppolu, B., Ravindranathan, S., Kurtz, S. L., Yang, L., Katz, M. D., & Zaharoff, D. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1672-x · Cited by 48
Self-citationPan, W., Lo, C.-H., Chen, C., Wu, P.-Y., Roffler, S. R., Shyue, S., & Tao, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.10 · Cited by 47
Iwanuma, Y., Chen, F.-A., Egilmez, N. K., Takita, H., & Bankert, R. B. (1997) · PubMed · Cited by 46
Salem, M. L., Kadima, A. N., Zhou, Y., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5159 · Cited by 46
Rodríguez-Madoz, J. R., Liu, K. H., Quetglas, J. I., Ruiz-Guillen, M., Otano, I., Crettaz, J. S., Butler, S. D., Bellezza, C. A., Dykes, N. L., Tennant, B. C., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01597-09 · Cited by 46
Triozzi, P. L., Strong, T. V., Bucy, R. P., Allen, K. O., Carlisle, R. R., Moore, S. E., LoBuglio, A. F., & Conry, R. M. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.91 · Cited by 45
Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer
Sabel, M. S., Su, G., Griffith, K. A., & Chang, A. E. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0570-3 · Cited by 45
Malvicini, M., Rizzo, M., Alaniz, L. D., Piñero, F., García, M. G., Atorrasagasti, C., Aquino, J. B., Rozados, V. R., Scharovsky, O. G., Matar, P., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1861 · Cited by 45
Thomas, E. D., Meza‐Perez, S., Bevis, K. S., Randall, T. D., Gillespie, G. Y., Langford, C. P., & Alvarez, R. D. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0282-3 · Cited by 45
IL-12 Gene Electrotransfer Triggers a Change in Immune Response within Mouse Tumors
Shi, G., Edelblute, C. M., Arpag, S., Lundberg, C. G., & Heller, R. F. (2018) · Cancers · doi:10.3390/cancers10120498 · Cited by 45
Chikkanna-Gowda, C. P., Sheahan, B. J., Fleeton, M. N., & Atkins, G. J. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302561 · Cited by 44
Charoensit, P., Kawakami, S., Higuchi, Y., Yamashita, F., & Hashida, M. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.12 · Cited by 43
Jahn, T., Zuther, M., Friedrichs, B., Heuser, C., Guhlke, S., Abken, H., & Hombach, A. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044482 · Cited by 43
Petry, H., Orme, A. E., Liu, P., Bauzone, M., Gibson, H. M., Qian, H. S., Rubanyi, G. M., & Harkins, R. N. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.1088 · Cited by 43
Semliki Forest virus-mediated gene therapy of the RG2 rat glioma
Roche, F. P., Sheahan, B. J., O’Mara, S. M., & Atkins, G. J. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01110.x · Cited by 42
Melero, I., Quetglas, J. I., Reboredo, M., Dubrot, J., Rodríguez-Madoz, J. R., Mancheño, U., Casales, E., Riezu‐Boj, J. I., Ruiz-Guillen, M., Ochoa, M. C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3356 · Cited by 42
Ji, Y. C., Liu, X., Huang, M. T.-H., Jiang, J., Liao, Y., Liu, Q., Chang, C. H., Liao, H., Lu, J., Wang, X., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.027 · Cited by 40
Watkins, S. K., Li, B., Richardson, K. S., Head, K. Z., Egilmez, N. K., Zeng, Q., Suttles, J., & Stout, R. D. (2009) · European Journal of Immunology · doi:10.1002/eji.200839010 · Cited by 39
Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity
Komita, H., Zhao, X., Katakam, A. K., Kumar, P., Kawabe, M., Okada, H., Braughler, J. M., & Storkus, W. J. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.33 · Cited by 39
Rubinstein, M. P., Cloud, C. A., Garrett, T. E., Moore, C. J., Schwartz, K. M., Johnson, B. C., Craig, D., Salem, M. L., Paulos, C. M., & Cole, D. J. (2012) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.12.034 · Cited by 39
Thaçi, B., Ahmed, A. U., Ulasov, I. V., Wainwright, D. A., Nigam, P., Auffinger, B., Tobias, A. L., Han, Y., Zhang, L., Moon, K.-S., et al. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2013.81 · Cited by 39
Tratar, U. L., Loiacono, L., Čemažar, M., Kamenšek, U., Fazio, V. M., Serša, G., & Signori, E. (2017) · Mediators of Inflammation · doi:10.1155/2017/5285890 · Cited by 39
Nair, R. E., Jong, Y. S., Jones, S. A., Sharma, A., Mathiowitz, E., & Egilmez, N. K. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175489.19314.d2 · Cited by 38
Cicchelero, L., Denies, S., Haers, H., Vanderperren, K., Stock, E., Brantegem, L. V., de Rooster, H., & Sanders, N. N. (2016) · Veterinary and Comparative Oncology · doi:10.1111/vco.12255 · Cited by 38
Jeong, K., Lee, E., Kim, S. J., Yang, S., Sung, Y. C., & Seong, J. (2015) · International Journal of Cancer · doi:10.1002/ijc.29428 · Cited by 37
Administration Route- and Immune Cell Activation-Dependent Tumor Eradication by IL12 electrotransfer
Li, S., Zhang, L., Torrero, M. N., Cannon, M. J., & Barret, R. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.037 · Cited by 37
Kilinc, M. O., Rowswell-Turner, R. B., Gu, T., Virtuoso, L. P., & Egilmez, N. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902625 · Cited by 37
Gao, M., Zhu, X., Wu, L., & Qiu, L. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b00433 · Cited by 37
Venetz, D., Koovely, D., Weder, B., & Neri, D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.737734 · Cited by 37
Sheikhsaran, F., Sadeghpour, H., Khalvati, B., Entezar-Almahdi, E., & Dehshahri, A. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.11.008 · Cited by 37
Morillon, Y. M., Su, Z., Schlom, J., & Greiner, J. W. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0620-2 · Cited by 37
Meraz, I. M., Savage, D. J., Segura-Ibarra, V., Li, J., Rhudy, J. R., Gu, J., & Serda, R. E. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5002697 · Cited by 36
Shibata, M., Ito, Y., Morimoto, J., Kusakabe, K. T., Yoshinaka, R., & Otsuki, Y. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.854 · Cited by 36
Kim, W., Seong, J., Oh, H. J. S., Koom, W. S., Kyung-Joo, C. H. O. I., & Yun, C. (2011) · Journal of Radiation Research · doi:10.1269/jrr.10185 · Cited by 35
Khalvati, B., Sheikhsaran, F., Sharifzadeh, S., et al. (2016) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2016.1202256 · Cited by 35
Sustained Release Technology and Its Application in Environmental Remediation: A Review
Wang, L., & Liu, X. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16122153 · Cited by 35
Sonabend, A. M., Velicu, S., Ulasov, I. V., Han, Y., Tyler, B., Brem, H., Matar, M. M., Fewell, J. G., Anwer, K., & Lesniak, M. S. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f24017 · Cited by 34
Guan, M., Rodríguez-Madoz, J. R., Alzuguren, P., Gomar, C., Kramer, M. G., Kochanek, S., Prìeto, J., Smerdou, C., & Qian, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0877 · Cited by 34
Harden, J. L., Gu, T., Kilinc, M. O., Rowswell-Turner, R. B., Virtuoso, L. P., & Egilmez, N. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100168 · Cited by 34
Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma
Sedlar, A., Kranjc, S., Dolinšek, T., Čemažar, M., Coer, A., & Serša, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-38 · Cited by 34
Nair, R. E., Kilinc, M. O., Jones, S. A., & Egilmez, N. K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7325 · Cited by 34
Eckert, F., Schmitt, J., Zips, D., Krueger, M. A., Pichler, B. J., Gillies, S. D., Strittmatter, W., Handgretinger, R., & Schilbach, K. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1863-0 · Cited by 34
Rodríguez-Calvillo, M., Duarte, M. C., Tirapu, I., Berraondo, P., Mazzolini, G. D., Qian, C., Prìeto, J., & Melero, I. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00792-5 · Cited by 33
Gabaglia, C. R., Durana, Y. D. D., Graham, F. L., Gauldie, J., Sercarz, E. E., & Braciak, T. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3399 · Cited by 33
Modulation of Interleukin-12 activity in the presence of heparin
Jayanthi, S., Koppolu, B., Nguyen, K. G., Smith, S. G., Felber, B. K., Kumar, T. K. S., & Zaharoff, D. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-05382-1 · Cited by 33
Self-citationBurkart, C., Mukhopadhyay, A., Shirley, S. A., Connolly, R. J., Wright, J. H., Bahrami, A. J., Campbell, J. S., Pierce, R. H., & Canton, D. A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0006-y · Cited by 33
Efficient Gene Delivery by EGF-LipoplexesIn VitroandIn Vivo
Buñuales, M., Düzgüneş, N., Zalba, S., Garrido, M. J., & de Ilarduya, C. T. (2010) · Nanomedicine · doi:10.2217/nnm.10.100 · Cited by 32
Vera, M., Razquin, N., Prìeto, J., Melero, I., Fortes, P., & González‐Aseguinolaza, G. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.030 · Cited by 31
Cody, J. J., Scaturro, P., Cantor, A. B., Gillespie, G. Y., Parker, J. N., & Markert, J. M. (2012) · International Journal of Breast Cancer · doi:10.1155/2012/628697 · Cited by 31
Molecular mechanisms of heparin-induced modulation of human interleukin 12 bioactivity
Nguyen, K. G., Gillam, F. B., Hopkins, J. J., Jayanthi, S., Gundampati, R. K., Su, G., Bear, J., Pilkington, G. R., Jalah, R., Felber, B. K., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006193 · Cited by 31
Self-citationHelguera, G. F., Rodríguez, J. A., & Penichet, M. L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0488 · Cited by 29
Osada, T., Berglund, P., Morse, M. A., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1248-y · Cited by 29
Sabel, M. S., Hill, H. C., Jong, Y. S., Mathiowitz, E., Bankert, R. B., & Egilmez, N. K. (2001) · Surgery · doi:10.1067/msy.2001.115839 · Cited by 29
Freytag, S. O., Zhang, Y., & Siddiqui, F. (2015) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2015.6 · Cited by 29
Andrews, K. J., Ribas, A., Butterfield, L. H., Vollmer, C. M., Eilber, F. C., Dissette, V. B., Nelson, S. D., Shintaku, P. I., Mekhoubad, S., Nakayama, T., et al. (2000) · PubMed · Cited by 28
Membrane‐tethered proteins for basic research, imaging, and therapy
Cheng, T., & Roffler, S. R. (2008) · Medicinal Research Reviews · doi:10.1002/med.20127 · Cited by 28
Han, J., Zhao, J., Xu, J.-R., & Wen, Y. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1918 · Cited by 28
Ring, E. K., Li, R., Moore, B. P., Nan, L., Kelly, V. M., Han, X., Beierle, E. A., Markert, J. M., Leavenworth, J. W., Gillespie, G. Y., et al. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.09.003 · Cited by 26
Huang, C., Ramakrishnan, R., Trkulja, M., Ren, X., & Gabrilovich, D. I. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1198-9 · Cited by 25
Nguyen, C. L., Bui, J. T., Demcheva, M. V., Vournakis, J. N., Cole, D. J., & Gillanders, W. E. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200109000-00004 · Cited by 25
Jayanthi, S., Koppolu, B., Smith, S. G., Jalah, R., Bear, J., Rosati, M., Pavlakis, G. N., Felber, B. K., Zaharoff, D. A., & Kumar, T. K. S. (2014) · Protein Expression and Purification · doi:10.1016/j.pep.2014.07.002 · Cited by 25
Self-citationSung, M. W., Chen, S., Thung, S. N., Zhang, D. Y., Huang, T.-G., Mandeli, J., & Woo, S. L. C. (2002) · Human Gene Therapy · doi:10.1089/104303402317322294 · Cited by 25
Hallaj‐Nezhadi, S., Valizadeh, H., Baradaran, B., et al. (2013) · Future Oncology · doi:10.2217/fon.13.82 · Cited by 24
Tumor Therapy Applying Membrane-bound Form of Cytokines
Kim, Y. S. (2009) · Immune Network · doi:10.4110/in.2009.9.5.158 · Cited by 24
Egilmez, N. K., Jong, Y. S., Hess, S. D., Jacob, J. S., Mathiowitz, E., & Bankert, R. B. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200003000-00003 · Cited by 24
Lin, L., Rayman, P. A., Pavicic, P. G., Tannenbaum, C. S., Hamilton, T. A., Montero, A. J., Ko, J. S., Gastman, B., Finke, J. H., Ernstoff, M. S., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2280-3 · Cited by 24
Li, X., Zhang, P., Liu, X., & Lv, P. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12151 · Cited by 22
Díaz-Montero, C. M., Naga, O. S., Zidan, A. A., Salem, M., Pallin, M., Parmigiani, A., Walker, G. R., Wieder, E., Komanduri, K. V., Cole, D. J., et al. (2011) · Europe PMC (PubMed Central) · Cited by 21
Gao, J., Sugita, T., Kanagawa, N., Iida, K., Eto, Y., Motomura, Y., Mizuguchi, H., Tsutsumi, Y. M., Hayakawa, T., Mayumi, T., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.061 · Cited by 21
Peng, L. S., Penichet, M. L., Cruz, J. S. D., et al. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/107999001753124444 · Cited by 21
Nahaei, M. R., Valizadeh, H., Baradaran, B., Nahaei, M. R., Asgari, D., Hallaj‐Nezhadi, S., Dastmalchi, S., & Lotfipour, F. (2013) · Drug Research · doi:10.1055/s-0032-1331165 · Cited by 21
Patterns of Vasculature in Mouse Models of Lung Cancer Are Dependent on Location
Vilalta, M., Hughes, N. P., von Eyben, R., Giaccia, A. J., & Graves, E. E. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1010-5 · Cited by 21
Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells
Goding, S. R., Yu, S., Bailey, L. M., Lotze, M. T., & Basse, P. H. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.06.013 · Cited by 20
Janat-Amsbury, M. M., Yockman, J. W., Lee, M., Kern, S. E., Furgeson, D. Y., Bikram, M., & Kim, S. W. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.015 · Cited by 19
The anti-angiogenic activity of IL-12 is increased in iNOS−/− mice and involves NK cells
Bielawska‐Pohl, A., Blesson, S., Benlalam, H., Trenado, A., Opolon, P., Bawa, O., Rouffiac, V., Duś, D., Kiéda, C., & Chouaı̈b, S. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0620-7 · Cited by 19
Hirschowitz, E. A., & Crystal, R. G. (1999) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.20.5.3412 · Cited by 17
Low-Dose Adenoviral Immunotherapy of Rat Hepatocellular Carcinoma Using Single-Chain Interleukin-12
Waehler, R., Ittrich, H., Müller, L. P., Krupski, G., Ameis, D., & Schnieders, F. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.307 · Cited by 17
Jackaman, C., & Nelson, D. J. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.85 · Cited by 17
Jia, S.-F., Duan, X., Worth, L. L., Guan, H., & Kleinerman, E. S. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700968 · Cited by 17
Kanagawa, N., Gao, J., Motomura, Y., Yanagawa, T., Mukai, Y., Yoshioka, Y., Okada, N., & Nakagawa, S. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.129 · Cited by 16
Rodríguez-Madoz, J. R., Zabala, M., Alfaro, M., Prìeto, J., Kramer, M. G., & Smerdou, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.080 · Cited by 15
Müller, J.-M. V., Wissemann, J., Meli, M. L., Dasen, G., Lutz, H., Heinzerling, L., & Feige, K. (2011) · Schweizer Archiv für Tierheilkunde · doi:10.1024/0036-7281/a000262 · Cited by 15
Chemotherapy-induced metastasis in breast cancer
Karagiannis, G. S., Condeelis, J. S., & Oktay, M. H. (2017) · Oncotarget · doi:10.18632/oncotarget.22717 · Cited by 15
Intratumoral injection of dendritic cells overexpressing interleukin‑12 inhibits melanoma growth
Yao, W., Li, Y., Zeng, L., Zhang, X., Zhou, Z., Zheng, M., & Wan, H. (2019) · Oncology Reports · doi:10.3892/or.2019.7165 · Cited by 14
Reay, J. C., Gambotto, A. A., & Robbins, P. D. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.78 · Cited by 12
Dehshahri, A., Sadeghpour, H., Keykhaee, M., Khalvati, B., & Sheikhsaran, F. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-016-1991-1 · Cited by 12
Growth Suppression of Human Laryngeal Squamous Cell Carcinoma by Adenoviral-mediated Interleukin-12
Tian, L., Chen, X., Sun, Y., Liu, M., Zhu, D., & Ren, J. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800326 · Cited by 12
Tanaka, K., Towata, S., Nakao, K., Mizuguchi, H., Hayakawa, T., Niwa, M., Ishii, N., & Nagayama, Y. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01915.x · Cited by 11
Luría-Pérez, R., Candelaria, P. V., Daniels‐Wells, T. R., Rodríguez, J. A., Helguera, G. F., & Penichet, M. L. (2019) · Cytokine · doi:10.1016/j.cyto.2019.04.004 · Cited by 8
Species‐specific differences in heparin‐induced modulation of IL‐12 family cytokines
Nguyen, K. G. (2019) · The FASEB Journal · doi:10.1096/fasebj.2019.33.1_supplement.lb334 · Cited by 3
Self-citation
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
The Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
IL-12 Family Cytokines in Cancer and Immunotherapy
Mirlekar, B., & Pylayeva-Gupta, Y. (2021) · Cancers · doi:10.3390/cancers13020167 · Cited by 295
Metadata
- Authors
- Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-10-15
- Volume
- 11
- Pages
- 575597-575597
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3093225819
- Cited by
- 431
- References
- 317
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.